Skip to main content
Premium Trial:

Request an Annual Quote

Valted Seq Lands Exclusive Rights to Evaluate Johns Hopkins Neurodegenerative Disease Dx Assays

NEW YORK – Valted Seq said on Thursday that it has obtained exclusive rights from Johns Hopkins University to evaluate biomarker assays that could be used to diagnose and manage neurodegenerative diseases.

Under the agreement, Valted Seq will have rights to develop biomarker assays focused on the poly(ADP-ribose) (PAR) and c-Abl pathways. The PAR assays can be used to diagnose Parkinson's disease from cerebral spinal fluid, serum, or plasma exosomes and the c-Abl pathway assays can diagnose Parkinson's and other α-synucleinopathies from serum or plasma exosome samples.

"Our sponsored research agreement with Johns Hopkins has been highly productive and the obvious next step was to bring this technology in house. This exclusive agreement will allow us to evaluate and optimize multiple PAR and c-Abl pathway biomarker assays for potential use in clinical applications," Isabell Loftin, Valted Seq's VP of diagnostics, said in a statement. Applications include screening, diagnosis, patient selection for clinical trials, disease progression monitoring, and evaluation of therapies for Parkinson's and related diseases, she added.

Founded in September 2020, Valted Seq is a subsidiary of South Korea's D&D Pharmatech. The firm is building a repository of single-cell sequencing data from patients with neurodegenerative diseases, including Alzheimer's and Parkinson's.

"There are currently no clinically accepted biomarker assays available for Parkinson’s disease," said Seulki Lee, Valted Seq's chairman and CEO of D&D Pharmatech, in a statement. "An assay capable of identifying disease-relevant biomarker results would provide high medical value to these patients."

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.